BofA/Merrill Lynch Upgrades Edwards Lifesciences (EW) to Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
Go back to BofA/Merrill Lynch Upgrades Edwards Lifesciences (EW) to Buy
July 27, 2016 10:15 AM EDT
Canaccord Genuity analyst Jason Mills reiterated a Buy rating and raised his price target on Edwards Lifesciences (NYSE: EW) to $140.00 (from $132.00) following the latest 'beat and raise'.
Mills commented, ""We view EW as one of the most attractive large-cap growth ideas in... More
July 27, 2016 8:14 AM EDT
UBS analyst Matt Miksic reiterated a Buy rating and boosted his price target on Edwards Lifesciences (NYSE: EW) to $139.00 (from $135.00) following strong results after the close.
Miksic commented, "Our intra-quarter checks indicated strong volume growth, contrary to Street concerns over third-party data indicating otherwise. However, EW delivered results... More
July 27, 2016 7:15 AM EDT
Leerink Partners analyst, Danielle Antalffy, reiterated her Outperform rating on shares of Edwards Lifesciences (NYSE: EW) after the company reported better than-expected sales (9th consecutive quarter of sales outperformance) -- with 2Q16 adjusted sales of $759.3M (+22.1% y/y, +22.9% ex. FX), ~$35M ahead of consensus. She also raised her price target to $130.00... More
July 26, 2016 4:17 PM EDT
Edwards Lifesciences (NYSE: EW) reported Q2 EPS of $0.76, $0.06 better than the analyst estimate of $0.70. Revenue for the quarter came in at $759.3 million versus the consensus estimate of $724.26 million.
"We are very pleased to report strong second quarter performance, which reflected significant growth in... More
